Global Liver Institute | Strategic Alliance Partnership

The first medication for the treatment of nonalcoholic steatohepatitis (NASH) and liver fibrosis received accelerated approval. Previously, the only treatment available to patients was implementing lifestyle changes aimed at weight reduction.

Jeff McIntyre, MA, of the Global Liver Institute (GLI), discusses the importance of the health care community understanding non-alcoholic steatohepatitis (NASH) and how to mitigate its global impact.

Jeff McIntyre, MA, of the Global Liver Institute, discussed how the delayed diagnosis of nonalcoholic steatohepatitis (NASH) affects patients and how health care and managed care professionals can help expedite diagnosis and treatment.

Two posters presented at The Liver Meeting identified the primary care coordinators for patients with nonalcoholic steatohepatitis (NASH) and areas of unmet need among specialists to provide optimal management.

The incidence of chronic liver disease is expected to sharply rise by 2030, making it important to understand the factors that influence patient outcomes.

GLI Spearheads Initiative to Double the Five-Year Survival Rate by 2030

October is Liver Cancer Awareness Month, an annual national awareness campaign centered around raising the voices of those impacted by liver cancer, showing the importance of liver cancer screening and prevention, and examining the future of the liver cancer landscape worldwide.

Key measures include calling for increased transparency and accountability in the performance of the nation’s 58 Organ Procurement Organizations (OPOs) and increasing and expanding the reimbursement for living donors.

In response to the Trump administration's 2020 Fiscal Year Budget Proposal, the Global Liver Institute (GLI) expressed its disappointment with the proposal, specifically with funding cuts to the National Institutes of Health (NIH).

The Global Liver Institute (GLI), along with other advocacy organizations, has sent a letter to CMS Administrator Seema Verma highlighting the United States' massive transplant waiting list, low organ recovery numbers, and need for change.

International NASH Day will be led by a new coalition of patient advocacy organizations and medical and professional societies, spearheaded by the Global Liver Institute.